Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects eligible for study entry will meet the following criteria:~* Male or female, ages at least 18 years and not over 55 years.~* Body mass index (BMI) within the range 20.0 to 30.0 kg/m2, inclusive.~* Applies to females only: Female subjects of childbearing potential with a nonsterilized male sexual partner must agree to use a hormonal contraceptive, barrier contraceptive with additional spermicide, or an intrauterine device beginning \> 30 days prior to the first dosing and continuing until \> 7 days after the end of the study. Female subjects who are postmenopausal must have been postmenopausal for \> 1 year if they wish not to use contraceptives.~* Good general health, evidenced by a lack of significantly abnormal findings on medical history and screening assessments.~* Pain intensity score of \> 30 mm on a VAS after incision and application of an 18% acetic acid solution to nontreated skin (i.e., not infiltrated with any test or control article) at Screening.~* Able and willing to comply with all study visits and procedures, including returning as scheduled for the second treatment visit.~* Able to speak, read, and understand the language of the ICF, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.~* Willing and capable of providing written informed consent.~Exclusion Criteria:~A subject will not be eligible for the study if he or she meets any of the following criteria:~* A history of hypersensitivity to amide type local anesthetics.~* Pregnancy, nursing, or planning to become pregnant during the course of the study.~* Any current conditions that might interfere with pain assessments, including current pain.~* Conditions of the skin or neurological abnormalities that might alter pain sensitivity. These include excessive scarring, burns, skin grafts, and trauma. Tattoos are permitted.~* A history of keloid formation.~* A coagulopathy or use of medications that might enhance bleeding.~* Use of any of the following medication within the times specified before study drug administration:~  * Long-acting opioid mediations within 3 days.~ * Any opioid medication within 24 hours.~ * Any analgesic medication within 12 hours.~* Consumption of alcohol within 24 hours before either treatment visit.~* Any condition that, in the opinion of the Investigator, renders a subject unsuitable for participation in the study. NOTE: The specific reason(s) for exclusion will be documented in the Screening Log.~* Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.~Minor deviations in eligibility criteria are permitted if approved by the Pacira Medical Monitor in agreement with the Investigator prior to dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- SKY0402 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).